HC Wainwright Rates Corcept Therapeutics (CORT) Buy

HC Wainwright reiterated its Buy rating on Corcept Therapeutics Incorporated CORT on September 18, 2026, keeping its price target at $165. The research note arrived as the biotechnology firm's shares closed at $110.29 on the day of the announcement.

CORT Corcept Therapeutics Incorporated

$111.49 ▲ +191.86% year to date

1M 3M YTD

Daily close · Oct 19, 2026

HC Wainwright's Call on Corcept Therapeutics

In its September 18 note, HC Wainwright maintained both its Buy rating and its $165 price target. The research represents a forward-looking view from the firm regarding the biopharmaceutical company's business outlook in the endocrine and metabolic treatment space.

Other Institutional Activity in Corcept Therapeutics

Large investors continue to make adjustments to their holdings in the biotechnology firm. Ingalls & Snyder LLC grew its holdings by 325,659 shares, ending with 7,934,507 shares worth about $889,458,222. Renaissance Technologies, LLC reduced its stake by 421,089 shares to finish with 5,261,628 shares valued at approximately $589,828,490. Parallel Advisors, LLC trimmed its position by 15,114 shares, leaving it with 3,962,177 shares worth roughly $444,160,035. AQR Capital Management, LLC grew its stake significantly by adding 2,176,357 shares for a total of 2,582,561 shares valued at about $289,505,084.

Corcept Therapeutics Incorporated Stock Down 0.9%

Corcept Therapeutics shares recently traded around $109.19 as of October 16, 2026, down about 1.0% since the September research note. The stock trades below its 50-day moving average of $115.66, but remains above its 200-day moving average of $72.15.

Recent Earnings

Corcept Therapeutics reported trailing-twelve-month revenue of $830,812,992 with an earnings per share of $0.45. The company's net profit margin sits at 6.6% alongside a return on equity of 8.2%. The firm is scheduled to release its next earnings report on November 4, 2026.

Insider Buying and Selling at Corcept Therapeutics Incorporated

Company insiders have recorded transactions in recent weeks. Chief Technology Officer Joseph Douglas Lyon disposed of 10,000 shares on September 14, 2026, with a total value of $1,134,947. Director James N Wilson parted with 10,000 shares on September 15, 2026, valued at $1,106,940.

Analysts Set New Price Targets

Across the broader analyst community, the stock holds a consensus buy rating with a mean price target of $141.00 drawn from 5 analyst opinions. Piper Sandler reiterated an overweight rating and lifted its target to $165.00 from $88.00 on July 30, 2026. HC Wainwright & Co. also maintained a Buy rating and raised its target to $165.00 from $95.00 on July 30, 2026.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a Redwood City, California-based biopharmaceutical enterprise focused on discovering and developing treatments for severe endocrine, oncologic, metabolic, and neurologic disorders.

Bottom Line

HC Wainwright's reaffirmed stance places its target at the high end of Wall Street expectations as the company approaches its upcoming earnings report on November 4, 2026. Investors will look to the upcoming financial results for further direction on the firm's growth trajectory.